Manufactures Active Pharmaceutical Ingredients (APIs) as its sole business segment, reporting FY26 revenue of Rs. 103.66 crore and net profit of Rs. 13.11 crore. The cost structure is led by raw materials and inputs at 41.2% of revenue, followed by other operating expenses at 35.7%, employee costs at 5.9% and depreciation at 3.6%, with capex at 1.9% of revenue. The standalone company has no subsidiaries, associates or joint ventures, ran with zero borrowings and held cash and equivalents of Rs. 4,184.29 lakh at FY26 year-end, alongside trade receivables of Rs. 1,671.41 lakh. Q4 FY26 total income fell to Rs. 1,961.08 lakh from Rs. 2,933.95 lakh in the preceding quarter, with Q4 net profit of Rs. 85.36 lakh. SEBI issued an ex-parte interim order and a confirmatory order restraining a proposed slump sale of the primary business to a related party; the company is evaluating legal remedies. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Active Pharmaceutical Ingredients (APIs). Single-segment, standalone Indian API manufacturer with no subsidiaries
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 75 | 96 | 96 | 101 | 104 |
| EBITDA (ex other income) | 16 | 18 | 23 | 20 | 17 |
| margin % | 21.7 | 19.0 | 23.9 | 19.3 | 16.5 |
| Owners' profit | 0 | 11 | 15 | 13 | 13 |
| EPS, as reported (₹) | 7.49 | 9.21 | 11.78 | 10.86 | 10.65 |
| ROE % · ROCE % | — · — | 15.9 · 20.3 | 16.9 · 22.0 | 13.5 · 17.5 | 11.7 · 15.1 |
| Debt / equity (x) | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 8 | 13 | 20 | 16 | 16 |
| Capex | (3) | (8) | (6) | (1) | (2) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 35 | 21 | 22 | 26 | 29 | 29 | 20 | 31 |
| Profit before tax | 11 | 1 | 2 | 4 | 6 | 6 | 1 | 6 |
| Net profit | 9 | 1 | 2 | 3 | 4 | 5 | 1 | 5 |
| EPS (₹) | 6.99 | 0.47 | 1.34 | 2.70 | 3.36 | 3.90 | 0.69 | 3.83 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 5 Sept 2026 · Newspaper publication of 27th AGM notice and e-voting information | compliance | minimal | — | — |
| 1 Sept 2026 · AGM Notice and Annual Report FY25-26 circulation to shareholders | compliance | minimal | — | — |
| 22 Aug 2026 · Par Drugs 27th AGM on Sep 26, 2026 - Notice and E-voting Details | board shareholder meetings | low | — | — |
| 22 Aug 2026 · Board meeting outcome: AGM notice, director pay hike, auditor reappointments | board shareholder meetings | low | — | — |
| 22 Aug 2026 · Board meeting outcome: AGM on Sep 26, auditor re-appointments, CEO and MD pay hike | management changes | low | — | — |
| 22 Aug 2026 · Board approves Cost Auditor re-appointment, raises MD and CEO pay | management changes | medium | — | — |
| 22 Aug 2026 · Board sets AGM date and seeks approval for higher director pay | board shareholder meetings | low | — | — |
| 21 Aug 2026 · Newspaper notice on IEPF transfer of shares for unclaimed dividends | compliance | minimal | — | — |
| 10 Aug 2026 · Par Drugs publishes Q1 FY27 results: PAT rises 42% YoY to Rs. 471.27 lakh | compliance | minimal | — | — |
| 8 Aug 2026 · Q1 FY27 results: Revenue up 20% YoY, PAT jumps 41.6% to Rs 4.71 cr | results | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 12.0 | 28.9 | 28 of 169 | 84% |
| P/B | 1.6 | 3.3 | 37 of 163 | 78% |
| ROCE | 15.0 | 10.8 | 64 of 183 | 65% |
| ROE | 11.7 | 10.4 | 71 of 171 | 59% |
| Debt / Equity | 0.0 | 0.1 | 6 of 171 | 77% |
| EBITDA margin | 23.4 | 17.5 | 60 of 165 | 64% |
| Revenue growth | 20.1 | 16.3 | 69 of 161 | 58% |
| Profit growth | 41.6 | 30.9 | 73 of 158 | 54% |
| Market cap | 174 | 839 | 119 of 182 | 35% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
